Scholars Central

Short communicationPublished 15 Sep 2023

Does left ventricular assist device increases risks for infections?

Authors: Rajendra Karnatak, Joseph V Vyskocil

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Left Ventricular Assist Device (LVAD) is used for the treatment of stage D heart failure as an alternative to heart transplantation. In recent years, LVAD use as destination therapy has significantly increased. One-year survival post-LVAD implantation is now comparable to heart transplantation. Recent data shows significant reductions in stroke and gastrointestinal bleeding in LVAD recipients, but infections remain a major concern. LVAD-mediated immune dysfunction has been reported in previous studies. Increasing LVAD utilization as destination therapy has shown improved long-term survival but the risk of infections with prolonged duration of LVAD support remained underexplored. In this article, we provide an overview of the infection risks associated with prolonged duration of LVAD support.

Subjects

Cardiology

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Interventional Cardiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInterventional Cardiology
  • SubjectCardiology
  • BylineArticles whose byline prints “Rajendra Karnatak”
  • BylineArticles whose byline prints “Joseph V Vyskocil”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels